Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease

The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration of approximately 4.1 billion USD, representing a premium of 28% to the 30-day volume-weighted average trading price as of April 22, 2026 The transaction marks Angelini Pharma's entry into the U.S. market, reinforcing its long-term commitment to Brain Health and its dedication to people living with Rare Diseases Closing is expected in the third quarter of 2026 ROME and CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Angelini Pharma S.p.A.